- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
WHO has published a global TB report every year since 1997. The main aim of the report is to provide a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease at global, regional and country levels. This is done in the context of recommended global TB strategies and targets endorsed by WHO’s Member States and broader development goals set by the United Nations.
About one-third of the world's population has latent TB, which means people have been infected by TB bacteria but are not (yet) ill with the disease and cannot transmit the disease.
People infected with TB bacteria have a 10% lifetime risk of falling ill with TB. However, persons with compromised immune systems, such as people living with HIV, malnutrition or diabetes, or people who use tobacco, have a much higher risk of falling ill.
Keywords: HIV, TB, diagnosis, treatment, prevention
For 2010–2016 implementation of the PhilPACT, the strategic thrust will be to (a) find the missing TB cases through expansion of diagnostic facilities and use of rapid diagnostic tests, full engagement of the private providers and hospitals and adoption of intensified case finding especially for the vulnerable populations; (b) expand PMDT facilities to improve access, hence, detect and treat more MDR-TB cases; (c) enhance services for the vulnerable populations who have higher risk of developing TB such as those with TB-HIV coinfection, the poor and children; (d) improve the human resource, logistical and information systems, and (e) strengthen the managerial capacity of all program managers.
The World Health Organization’s (WHO’s) End TB Strategy calls for the early diagnosis of tuberculosis (TB) including universal drug-susceptibility testing (DST). A prerequisite for any national TB programme to reach this goal is a quality-assured laboratory network equipped with rapid diagnostics. This Framework of indicators and targets for laboratory strengthening under the End TB Strategy serves as a guide for all countries developing plans for laboratory strengthening during 2016–2025. The indicators measure programmes’ capacity to detect TB accurately and rapidly using new diagnostics (known as WHO-recommended rapid diagnostics, or WRDs), provide universal DST, and ensure the quality of testing.
Keywords: HIV, tuberculosis (TB), diagnosis, data, testing, laboratory services
TB is one of the world's top health challenges. More than 2.4 billion people, equal to a one third of the world's population are infected with TB. 3.5 people are either not diagnosed. The proportions of missed cases remains the same each year. Many of those missed will either die, follow some unknown treatment but most will continue to infect others.
In 2014, the Sixty-seventh World Health Assembly endorsed the Global strategy and targets for tuberculosis prevention, care and control after 2015, also known as The End TB Strategy. The strategy aims to “end the global TB epidemic” by 2035, bringing the level of disease burden in the whole world down to the level seen now in countries with the lowest TB burden. Within the scope of this 20-year time span, this regional framework focuses on the implementation of The End TB Strategy in the coming five years.
Keywords: TB, HIV, treatment, drug-resistant, response
The Global TB Programme of WHO in collaboration with the Republic of Korea’s Centers for Disease Control and Prevention and International Tuberculosis Research Center organized a global consultation on the management of latent tuberculosis infection (LTBI) that was held during April 27–28, 2016, in Seoul, Republic of Korea. The objective of the meeting was to present and discuss challenges to, opportunities for, and best practices on the programmatic management of LTBI, and to consider recommendations to facilitate its implementation in both high-burden and low-burden countries.
The use of delamanid in the treatment of MDR-TB was recommended by the World Health Organization (WHO) in 2014. However, due to the lack of evidence on the use of delamanid in the paediatric populations, these interim policy recommendations were limited to adult MDR-TB patients under very strict conditions. In view of recent data on the use of delamanid in children diagnosed with MDR-TB, WHO convened an independent, multidisciplinary, international expert panel to assess new data and develop an addendum to the 2014 interim guidance on delamanid, with specific recommendations to paediatric MDR-TB patients.
TB is curable, but 37,000 people die every year from this airborne disease in our region - that’s almost five deaths every hour. Despite the shocking statistics and the heart-wrenching stories, international financial support for TB programmes in the European region is declining. These factsheets give a snapshot view of the TB burden in the countries.
Tuberculosis (TB) remains an important global health problem. Although a number of important advances have been made to control TB in the past decade, an estimated 10.4 million people fell ill with TB and 1.8 million died from the disease in 2015. WHO’s Global TB Programme has identified research and innovation as one of the three essential pillars to end TB as a public health threat by 2030. This document provides the structure and tools that enable the necessary actions to be taken to address country-specific TB challenges and ensure that national response activities are supported by evidence to the fullest extent possible.
This document describes how to develop a country-specific approach to utilizing research and innovation to strengthen and improve TB care and control. It provides a series of tools for developing and implementing a national TB research plan that will help in leveraging individual country action to address the global TB burden. These tools will assist a country’s national TB control programme or its equivalent to develop an effective national TB research plan through a coherent step-by-step process.